Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

Zurück zum Zitat Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186–e193CrossRefPubMedPubMedCentral Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186–e193CrossRefPubMedPubMedCentral

Zurück zum Zitat Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M et al (2020) Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol 301:163–166CrossRefPubMed Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M et al (2020) Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol 301:163–166CrossRefPubMed

Zurück zum Zitat Caocci G, Atzeni S, Orrù N, Azzena L, Martorana L, Littera R, Ledda A, la Nasa G (2008) Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 22(11):2127–2128CrossRefPubMed Caocci G, Atzeni S, Orrù N, Azzena L, Martorana L, Littera R, Ledda A, la Nasa G (2008) Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 22(11):2127–2128CrossRefPubMed

Zurück zum Zitat Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner G-H, Sperr WR, Kirchmair R, Wolf D (2017) Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 59:47–54CrossRefPubMedPubMedCentral Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner G-H, Sperr WR, Kirchmair R, Wolf D (2017) Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 59:47–54CrossRefPubMedPubMedCentral

Zurück zum Zitat Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet Lond Engl. 360(9349):1903–1913CrossRef Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet Lond Engl. 360(9349):1903–1913CrossRef

Zurück zum Zitat Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group, de Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cífková R, Cleland JGF, Collet JP, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener HC, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muiesan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewics A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Mancia G, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafov R, Pavlova O, de Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavlukis M, Halimi JM, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercuro G, Bajraktari G, Romanova T, Trušinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aksnes TA, Jankowski P, Polonia J, Vinereanu D, Baranova EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, Backer TD, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Trušinskis K, Miglinas M, Gerdts E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 39(33):3021–3104CrossRefPubMed Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group, de Backer G, Heagerty AM, Agewall S, Bochud M, Borghi C, Boutouyrie P, Brguljan J, Bueno H, Caiani EG, Carlberg B, Chapman N, Cífková R, Cleland JGF, Collet JP, Coman IM, de Leeuw PW, Delgado V, Dendale P, Diener HC, Dorobantu M, Fagard R, Farsang C, Ferrini M, Graham IM, Grassi G, Haller H, Hobbs FDR, Jelakovic B, Jennings C, Katus HA, Kroon AA, Leclercq C, Lovic D, Lurbe E, Manolis AJ, McDonagh TA, Messerli F, Muiesan ML, Nixdorff U, Olsen MH, Parati G, Perk J, Piepoli MF, Polonia J, Ponikowski P, Richter DJ, Rimoldi SF, Roffi M, Sattar N, Seferovic PM, Simpson IA, Sousa-Uva M, Stanton AV, van de Borne P, Vardas P, Volpe M, Wassmann S, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Zamorano JL, Tsioufis C, Lurbe E, Kreutz R, Bochud M, Rosei EA, Jelakovic B, Azizi M, Januszewics A, Kahan T, Polonia J, van de Borne P, Williams B, Borghi C, Mancia G, Parati G, Clement DL, Coca A, Manolis A, Lovic D, Benkhedda S, Zelveian P, Siostrzonek P, Najafov R, Pavlova O, de Pauw M, Dizdarevic-Hudic L, Raev D, Karpettas N, Linhart A, Olsen MH, Shaker AF, Viigimaa M, Metsärinne K, Vavlukis M, Halimi JM, Pagava Z, Schunkert H, Thomopoulos C, Páll D, Andersen K, Shechter M, Mercuro G, Bajraktari G, Romanova T, Trušinskis K, Saade GA, Sakalyte G, Noppe S, DeMarco DC, Caraus A, Wittekoek J, Aksnes TA, Jankowski P, Polonia J, Vinereanu D, Baranova EI, Foscoli M, Dikic AD, Filipova S, Fras Z, Bertomeu-Martínez V, Carlberg B, Burkard T, Sdiri W, Aydogdu S, Sirenko Y, Brady A, Weber T, Lazareva I, Backer TD, Sokolovic S, Jelakovic B, Widimsky J, Viigimaa M, Pörsti I, Denolle T, Krämer BK, Stergiou GS, Parati G, Trušinskis K, Miglinas M, Gerdts E, Tykarski A, de Carvalho Rodrigues M, Dorobantu M, Chazova I, Lovic D, Filipova S, Brguljan J, Segura J, Gottsäter A, Pechère-Bertschi A, Erdine S, Sirenko Y, Brady A (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 39(33):3021–3104CrossRefPubMed

Zurück zum Zitat Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P (2017) Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 31(11):2388–2397CrossRefPubMedPubMedCentral Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P (2017) Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 31(11):2388–2397CrossRefPubMedPubMedCentral

Zurück zum Zitat Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM (2014) Angiotensin II and vascular injury. Curr Hypertens Rep 16(6):431CrossRefPubMed Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM (2014) Angiotensin II and vascular injury. Curr Hypertens Rep 16(6):431CrossRefPubMed

Zurück zum Zitat Marusic-Vrsalovic M, Dominis M, Jaksic B, Kusec R (2003) Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol. 123(3):539–541CrossRefPubMed Marusic-Vrsalovic M, Dominis M, Jaksic B, Kusec R (2003) Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol. 123(3):539–541CrossRefPubMed

Zurück zum Zitat Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U, The Turkish CML Study Group (2009) Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. J Int Med Res. 37(4):1018–1028CrossRefPubMed Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U, The Turkish CML Study Group (2009) Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. J Int Med Res. 37(4):1018–1028CrossRefPubMed

Zurück zum Zitat Beyazit Y, Purnak T, Guven GS, Haznedaroglu IC (2010) Local bone marrow renin-angiotensin system and atherosclerosis. Cardiol Res Pract. 2011:714515PubMedPubMedCentral Beyazit Y, Purnak T, Guven GS, Haznedaroglu IC (2010) Local bone marrow renin-angiotensin system and atherosclerosis. Cardiol Res Pract. 2011:714515PubMedPubMedCentral

Zurück zum Zitat Haznedaroglu IC, Beyazit Y (2010) Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin-Angiotensin-Aldosterone Syst JRAAS. 11(4):205–213CrossRefPubMed Haznedaroglu IC, Beyazit Y (2010) Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin-Angiotensin-Aldosterone Syst JRAAS. 11(4):205–213CrossRefPubMed

Zurück zum Zitat Fukuda D, Sata M (2008) Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol Ther. 118(2):268–276CrossRefPubMed Fukuda D, Sata M (2008) Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol Ther. 118(2):268–276CrossRefPubMed

Zurück zum Zitat Schmieder RE, Volpe M, Waeber B, Ruilope LM (2014) A guide for easy- and difficult-to-treat hypertension. Int J Cardiol. 172(1):17–22CrossRefPubMed Schmieder RE, Volpe M, Waeber B, Ruilope LM (2014) A guide for easy- and difficult-to-treat hypertension. Int J Cardiol. 172(1):17–22CrossRefPubMed

Zurück zum Zitat Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WMM et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 19(4):403–488CrossRefPubMed Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WMM et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 19(4):403–488CrossRefPubMed

Zurück zum Zitat Wu C-H, Mohammadmoradi S, Chen JZ, Sawada H, Daugherty A, Lu HS (2018) Renin-angiotensin system and cardiovascular functions. Arterioscler Thromb Vasc Biol. 38(7):e108–e116CrossRefPubMedPubMedCentral Wu C-H, Mohammadmoradi S, Chen JZ, Sawada H, Daugherty A, Lu HS (2018) Renin-angiotensin system and cardiovascular functions. Arterioscler Thromb Vasc Biol. 38(7):e108–e116CrossRefPubMedPubMedCentral

Zurück zum Zitat Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W (2018) The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 25(2):137–145CrossRef Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W (2018) The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 25(2):137–145CrossRef

Zurück zum Zitat Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, de Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, la Nasa G, Foà R, Breccia M (2018) Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis. Am J Hematol. 93(7):E159–E161CrossRefPubMed Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, de Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, la Nasa G, Foà R, Breccia M (2018) Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis. Am J Hematol. 93(7):E159–E161CrossRefPubMed

Zurück zum Zitat Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S et al (2015) Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol 43(12):1015–1018.e1CrossRefPubMed Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S et al (2015) Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol 43(12):1015–1018.e1CrossRefPubMed

Zurück zum Zitat Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D (2018) Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front Oncol. 8:194CrossRefPubMedPubMedCentral Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D (2018) Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front Oncol. 8:194CrossRefPubMedPubMedCentral

Zurück zum Zitat Alhawiti N, Burbury KL, Kwa FA, O’Malley CJ, Shuttleworth P, Alzard M et al (2016) The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 145:54–64CrossRefPubMed Alhawiti N, Burbury KL, Kwa FA, O’Malley CJ, Shuttleworth P, Alzard M et al (2016) The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 145:54–64CrossRefPubMed